Skip to main content

Table 9 USA hCG Reference Service experience, concentration of hCG, hyperglycosylated hCG and hyperglycosylated hCG free β (HhCG β) in serum samples in gestational trophoblastic diseases and non-gestational malignancies.

From: New discoveries on the biology and detection of human chorionic gonadotropin

Source n Total hCG mIU/ml median (range) hCG-H mIU/ml molar1 % total hCG ± SD? HhCGβ mIU/ml molar1 % total hCG ± SD
Complete hydatidiform mole
(prior to evacuation)
30 192,995
(24160 – 3704084)
4.9 ± 2.1% 7.1 ± 20%3
Partial hydatidiform mole
(prior to evacuation)
21 48,900
(11600 – 220114)
3.6 ± 1.7% 5.8 ± 22%3
Invasive mole, recurrent mole
(at commencement of therapy)
72 869
(24 – 30255)
30 ± 35% 7.7 ± 11%
PSTT
(at time of diagnosis)2
21 30
(1 – 231)
7.1 ± 13% 61 ± 21%
Highly invasive Choriocarcinoma
> 50% hyperglycosylated hCG2
17 45,350
(3,020 – 596,600)
98 ± 5% 7.8 ± 8.4%
Invasive Choriocarcionoma
< 50% hyperglycosylated hCG
44 4,258
(108 – 10,245)
32 ± 11% 6.4 ± 7.5%
Quiescent GTD
(at time of diagnosis)2
93 22
(1 – 212)
0.10% ± 0.72% 2.7 ± 8.4%
Other gynecologic malignancies
(at time of diagnosis)2
14 33
(0.5 – 474)
0.55 ± 1.3% 91 ± 11%
  1. SD is standard deviation. Choriocarcinoma cases are those with and without histology (GTN).
  2. 1Values are measured in molar units and converted to equivalents of hCG, assuming that 1 ng/ml hCG is 11 mIU/ml (using hCG 1st RR standard).
  3. 2As measured by USA hCG Reference Service, indicated diagnosis confirmed at biopsy by referring center
  4. 3 As published by Van Trommel et al. (45).